Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves by Rajput, Neetu et al.
JOURNAL OF
Veterinary 
Science
J. Vet. Sci. (2007), 8(1), 21–25
Disposition kinetics and urinary excretion of cefpirome after intravenous 
injection in buffalo calves
Neetu Rajput, Vinod K. Dumka, Harpal S. Sandhu*
Department of Pharmacology and Toxicology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences 
University, Ludhiana-141004, India
We investigated the disposition kinetics and urinary
excretion of cefpirome in buffalo calves after a single
intravenous administration of 10 mg/kg. Also, an appropriate
dosage regimen was calculated. At 1 min after injection,
the concentration of cefpirome in the plasma was 57.4 ±
0.72 µg/ml, which declined to 0.22 ± 0.01 µg/ml at 24 h.
The cefpirome was rapidly distributed from the blood to
the tissue compartment as shown by the high distribution
coefficient values (8.67 ± 0.46/h), and by the drug’s rate of
transfer constant from the central to the peripheral
compartment, K12 (4.94 ± 0.31/h). The elimination half-
life and the volume of distribution were 2.14 ± 0.02 h and
0.42± 0.005l/kg, respectively. Once the distribution equilibrium
was reached between the tissues and plasma, the total
body clearance (ClB) and the ratio of the drug present in
the peripheral to the central compartment (T/P ratio) were
0.14 ± 0.002 l/kg/h
 and 1.73 ± 0.06, respectively. Based on
the pharmacokinetic parameters we obtained, an appropriate
intravenous cefpirome dosage regimen for treating cefpirome-
sensitive bacteria in buffalo calves would be 8.0 mg/kg
repeated at 12 h intervals for 5 days, or until persistence
of the bacterial infection occurred.
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Introduction
Cefpirome is a cephalosporin that was recently introduced,
and is frequently used for empirical therapy in severely ill
patients in the intensive care, oncology, and transplantation
units [20]. It has potent bactericidal activity against a broad
range of gram-negative and gram-positive organisms, including
Pseudomonas aeruginosa and methicillin susceptible
Staphylococcus  spp. It is also highly active against
Haemophillus influenzae type B and many members of the
Enterobacteriaceae  family [3]. Cefpirome, however, does
not target anaerobic bacteria; hence, it spares the intestinal
flora, unlike other antibiotics [7]. The disposition kinetics of
cefpirome have been investigated in humans [18], rabbits
[13], rats [8], dogs [11], and monkeys [12]. However, there
is no information available on cefpirome’s pharmacokinetics
in buffaloes. Given the marked species variations that are
found in the kinetic data of antimicrobial drugs, the present
study was undertaken to determine the disposition kinetics,
urinary excretion, and appropriate dosage regimen for
cefpirome in buffalo calves, following a single intravenous
administration.
Materials and Methods
The experiment was performed on 5 healthy male buffalo
calves, 6-12 months old and weighing 90-122 kg. The
animals were adapted to the laboratory conditions for 2
weeks prior to the study’s commencement, and were
provided seasonal green fodder, wheat straw, and water  ad
libitum. The average daytime temperature in the shed was
approximately 25
oC during the experimental period. The
experimental protocol followed the ethical guidelines on the
proper care and use of animals. Cefpirome (Orchid Chemicals
& Pharmaceuticals, India) was administered at a dose rate of
10 mg/kg of body weight into the left jugular vein. Blood
samples were then drawn from the contra lateral jugular vein
into heparinized glass centrifuge tubes at 1, 2.5, 5, 7.5, 10,
15, 30, 45 min, and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 14, and
24 h after administration of drug. The plasma was separated
by centrifugation at 3,000 rpm at room temperature and
stored at −20
oC until analysis, which usually took place the
day after collection.
To examine the urinary excretion of cefpirome, the same
animals were placed into metabolic stalls designed in such a
way that all the urine voided by the animals was collected
without contamination or spillage. The urine samples were
collected after predetermined time intervals of 2, 4, 6, 8, 10,
12, 14, and 24 h after drug administration. The volume of
urine was measured, and after filtration, 10 ml samples were
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taken for analysis.
The concentrations of cefpirome in the plasma and urine
samples were determined by a standard microbiological
bioassay technique [2] using Escherichia coli (MTCC 739)
as the test organism. The test organisms were cultured on
medium No. 1 at 37
oC for 24 h, and a suspension was
prepared in sterile normal saline. The assay plates were
prepared by putting a seed layer (25 ml) of medium No. 11
on the flat bottoms of assay Petri dishes that had 100 ml
capacities. A desired amount of bacterial suspension was
added to the seed layer to obtain clear bacterial growth and
the required zone of inhibition dimensions using a cefpirome
reference concentration of 0.25 µg/ml. Preliminary experiments
were conducted to determine the actual amount of bacterial
suspension to be used in the preparation of the seed layer.
After solidification of the media, 6 wells were punched at
equal distances using a punching machine (designed and
standardized in our laboratory). Three alternating cylindrical
wells were filled with one plasma or urine sample and the
remaining 3 cylindrical wells were filled with a standard
solution of cefpirome (0.25 µg/ml). These assay plates were
incubated at 32
oC for 6 h. At the end of incubation the
diameter of the zone of inhibition of each well was measured
with Antibiotic Zone Reader (Fisher Scientific, USA). For
each sample, 9 replicates were analyzed. This method could
detect a minimum of 0.05 µg/ml of cefpirome.
The pharmacokinetic parameters were calculated manually
by the computed least-square linear regression technique
[6]. Different estimates of the distribution volume were
obtained from the following equation:
The priming (D) and maintenance (D') doses of cefpirome
at various dosage intervals for maintaining different MICs
was calculated from the equations:
D = Cp(min)
∝ · Vdarea · (e
βτ)
D' = Cp(min)
∝ · Vdarea · (e
βτ – 1)
Where β is the elimination rate constant, τ is the dosage
interval, and Cp(min)
∝ is the minimum inhibitory concentration
of cefpirome against common animal pathogens.
Results
The plasma levels of cefpirome at different time intervals
are presented in Fig. 1. The plasma concentration of cefpirome
at 1 min after a single intravenous injection was 57.4 ± 0.72
µg/ml, which declined rapidly to 13.5 ± 0.11 µg/ml at 1 h.
The drug was detected in plasma for up to 24 h after dosing
(0.22 ± 0.01 µg/ml). The calculated pharmacokinetic
parameters that described the distribution and elimination
pattern of cefpirome are presented in Table 1. Table 2
summarizes the urinary excretion data of cefpirome after a
single intravenous administration. The optimum cefpirome
doses were calculated using the various dosage intervals, the
different desired plasma concentrations ranging from 0.05 to
0.5 µg/ml, and the values for β and Vdarea from Table 1.
These optimum doses are presented in Table 3.
Discussion
In buffalo calves, the disposition of cefpirome in plasma
after IV administration was best described by a 2-compartment
open pharmacokinetic model. Similarly, cefpirome was
Vdarea Dose mg/kg ()
β AUC ⋅
---------------------------------- =
VdB Dose mg/kg ()
B
---------------------------------- =
VdSS Dose mg/kg () AUMC ⋅
AUC
2 ---------------------------------------------------------- =
Fig. 1. Semilogarithmic plot of the plasma concentration-time
profile of cefpirome in buffalo calves following a single intravenous
dose of 10 mg/kg body weight. Values given are mean ± SE of 5
animals. The data were analyzed using a two-compartment ope n
model. Distribution (α) and elimination (β) phases are
represented by least-square regression lines. The calculate d
points (o) of the distribution phase were obtained by the
feathering off technique. 
Footnote: MIC; minimum inhibitory concentration, AUC; area under the
plasma concentration-time-curve, AUMC; area under the first moment
of the plasma concentration-time-curve, Cp = plasma drug concentration,
Vdarea, VdB, and Vdss; volume of distribution from AUC, elimination
phase, and steady state plasma level, respectively.Disposition kinetics of cefpirome in calves 23
reported as best fitting a 2-compartment open model after
intravenous administration in humans [14]. Also, this model
has been described for the disposition of ceftazidime in
cows [17], and cefepime in foals [5], and dogs [15].
At 1 min after injection, the plasma level (57.4 ± 0.72 µg/
ml) was approximately 147-fold higher than the minimum
therapeutic level of cefpirome (0.39 µg/ml), and the drug
was detected above the MIC for up to 14 h. In humans, a
high serum level of 44.4 µg/ml
 was attained at 0.2 h following
a 1 g intravenous dose of cefpirome [10]. Similarly, a peak
serum level of 47-49 µg/ml
 was reported in humans receiving
1 g of cefpirome intravenously [16]. A C max of 2.13 µg/ml in
the pouch exudate of rats was achieved after intravenous
administration of cefpirome at a dose rate of 40 µg/kg [1].
The minimum therapeutic plasma concentration of cefpirome
against most common pathogens in animals has been
reported as 0.05-0.39 µg/ml [1,9]. Due to the influence of
certain unavoidable factors in vivo, and to cover most of the
susceptible microorganisms, the higher MIC range (0.39 µg/
ml) of cefpirome has been taken into consideration for this
discussion.
The low distribution half-life (τ½α) value of cefpirome
(0.08 ± 0.004 h) indicated the drug’s rapid distribution from
the central to peripheral compartments in buffalo calves.
The rapid distribution of cefpirome was further confirmed
by the high K12/K21 ratio (1.56 ± 0.05).
The low Vdarea (0.42 ± 0.005 l/kg) in buffalo calves
indicated the limited distribution of cefpirome into various
body fluids and tissues. Low values of Vd area have been also
reported in mice (0.26 l/kg) and dogs (0.22 l/kg) after single
intravenous administration of cefpirome [11]. However, our
results are in contrast to the high Vdarea (1.3 ± 0.06 l/kg)
value that was reported after the repeated administration of
cefotaxime in buffalo calves [19]. Furthermore, the T/P ratio
Table 1. Disposition kinetic parameters of cefpirome in buffalo calves following a single intravenous administration
Pharmacokinetic Parameter
Calf number
Mean ± SE
12345
Cp
o (µg/ml) 66.200 62.400 65.600 70.200 59.900 64.8 ± 1.750
t½α (h) 0.08 0.09 0.08 0.07 0.08 0.08 ± 0.004
t½β ( h ) 2 . 1 72 . 1 72 . 1 72 . 1 02 . 1 02 . 1 4   ± 0.020
K12/K21 (ratio) 1.64 1.44 1.57 1.68 1.44 1.56 ± 0.050
AUC (µg · h/ml) 72.700 74.500 74.400 74.600 69.900 73.2 ± 0.900
AUMC (µg · h
2/ml) 210.7000 216.7000 216.8000 212.5000 199.3000 211.2 ± 3.2100
Vdarea (l/kg) 0.43 0.42 0.42 0.41 0.43 0.42 ± 0.005
VdB (l/kg) 0.47 0.45 0.45 0.43 0.46 0.45 ± 0.006
VdSS (l/kg) 0.40 0.39 0.39 0.38 0.41 0.40 ± 0.004
ClB (l/kg/h) 0.14 0.13 0.13 0.13 0.14 0.14 ± 0.002
Kel (/h) 0.91 0.84 0.88 0.94 0.86 0.89 ± 0.020
M R T  ( h ) 2 . 9 02 . 9 12 . 9 22 . 8 52 . 8 52 . 8 9  ± 0.010
T / P  ( r a t i o ) 1 . 8 51 . 6 21 . 7 61 . 8 51 . 6 01 . 7 3  ± 0.060
tCther ( h ) 7 . 0 47 . 0 47 . 0 46 . 8 16 . 8 16 . 9 5  ± 0.060
Cp
o = plasma drug concentration at zero time; t 1/2α and t1/2β = half-lives of distribution and elimination phases, respectively; K 12 and K21 = rate constants
defined in the two compartment model; AUC = area under the plasma concentration-time-curve; AUMC = area under the first moment of t he plasma
concentration-time-curve; Vd area, VdB, and Vdss = volume of distribution from AUC, elimination phase, and steady state plasma level, respectively; Cl B
= total body clearance of the drug; K el = elimination rate constant from the central compartment; MRT = mean residence time of drug in body; T/P =
ratio of the drug present in the peripheral to central compartment; tC ther = duration of therapeutic concentration of drug.
Table 2. Urinary excretion of cefpirome in healthy buffalo calves following a single intravenous administration
Time interval
(h)
Amount excreted 
(mg)
Per cent of total
dose excreted
Time interval
(h)
Cumulative amount 
excreted (mg)
Cumulative per cent 
of total dose excreted
0-2 356.5 ± 55.30 31.6 ± 5.16 0-2 356.5 ± 55.3 31.6 ± 5.16
2-4 179.5 ± 30.80 17.0 ± 3.45 0-4 464.7 ± 62.5 42.3 ± 4.82
4-6 133.5 ± 35.00 12.9 ± 4.30 0-6 571.5 ± 32.6 52.7 ± 0.63
6-8 54.0 ± 13.8 5.10 ± 0.64 0-8 593.1 ± 34.3 54.7 ± 1.18
8-10 23.8 ± 2.85 2.08 ± 0.27 0-10 607.4 ± 39.2 55.9 ± 1.44
10-12 14.5 ± 5.21 1.30 ± 0.52 0-12 616.0 ± 40.6 56.7 ± 1.51
12-14 10.3 ± 2.90 0.96 ± 0.22 0-14 622.2 ± 40.0 57.3 ± 1.34
14-24 12.4 ± 0.95 1.15 ± 0.10 0-24 634.6 ± 40.1 58.5 ± 1.3124 Neetu Rajput et al.
of 1.73 ± 0.06 that we observed when the distribution
equilibrium was reached between tissues and plasma
reflected higher cefpirome concentrations in the body fluids
and tissues as compared to the plasma of the buffalo calves.
The high AUC (73.2 ± 0.90 µg · h/ml) and AUMC (211.2
± 3.21 µg·h
2/ml) values reflected that a vast body area was
covered by cefpirome in the buffalo calves. Similarly, high
AUC values following single intravenous injection of
cefpirome were reported to be 75.6 µg · h/ml in rabbits [9],
20.1 µg · h/ml in mice, 103 µg · h/ml in dogs [11], 18.9 µg·
min/ml
 in rabbits [13], and 16.5 g · min/l in humans [18 ].
The total body clearance (ClB) of cefpirome, which
represents the sum of the metabolic and excretory processes,
was 0.14 ± 0.002 l/kg/h in the buffalo calves. Comparable
values of ClB were reported for cefpirome in dogs (3.2 ml/
kg/min), guineapigs (1.57 ml/kg/min), and humans (1.8 ml/
kg/min) following single intravenous injections [11]. Also,
similar value of ClB was reported after intravenous injection
of ceftriaxone (0.26 l/kg/h) in buffalo calves [4].
The elimination half-life of cefpirome in the buffalo
calves was 2.14 ± 0.02 h. Previously reported values of τ1/2β
have been 0.47 h in rabbits [9], 0.4 h in rats [8], 0.19 h in
mice [11], 0.9 and 1.1 h in dogs [8,11], and 1.95 h in humans
[16].
The elimination rate constant of cefpirome from the central
compartment (Kel) was 0.89 ± 0.02/h for the buffalo calves.
The values of MRT and tCther of cefpirome were 2.89 ±
0.01 h and 6.95 ± 0.06 h, respectively. Others have reported
Kel, MRT, and tCther values for ceftriaxone in buffalo calves
as 2.28/h, 2.04 h, and 25.1 h, respectively, [4].
The highest urinary excretion amount of the drug was at
0-2 h (356.5 ± 55.3 mg), which gradually declined to 12.4 ±
0.95 mg at 14-24 h. About 58.5% of the administered dose
was recovered in the urine within 24 h of administration. In
contrast, very high amounts of cefpirome were detected in
the urine of dogs (80%) and rats (90%) within 24 h after IV
dosing of cefpirome [8, 12]. However, Mrestani et al. [13]
reported a very low amount of cefpirome, only 2%, in rabbit
urine within 6 h after intraduodenal administration. A similar
level of urinary excretion was reported for ceftriaxone in
buffalo calves, where 49% of the administered dose was
recovered in the urine within 8 h [4].
The main objective of this pharmacokinetic study was to
compute the most appropriate dosage regimen of cefpirome
for buffalo calves. The most appropriate priming and
maintenance doses of cefpirome to maintain a MIC of 0.39
mg/ml at a dosage interval of 12 h would be 8.05 and 7.88
mg/kg, respectively. Under field conditions, a dose of 8.0
mg/kg may be needed at repeated 12 h intervals for 5 days,
or until persistence of the bacterial infection occurs.
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